Drug Profile
Seviteronel - Innocrin Pharmaceuticals
Alternative Names: INO-464; VT-464Latest Information Update: 08 Feb 2023
Price :
$50
*
At a glance
- Originator Viamet Pharmaceuticals
- Developer Innocrin Pharmaceuticals
- Class Antiandrogens; Antineoplastics; Fluorine compounds; Naphthalenes; Propanols; Small molecules; Triazoles
- Mechanism of Action Androgen receptor antagonists; Estrogen receptor antagonists; Steroid 17-alpha-hydroxylase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase II Breast cancer; Prostate cancer; Solid tumours
- Phase I/II Triple negative breast cancer
Most Recent Events
- 01 Jul 2022 Phase-I/II clinical trials in Triple-negative-breast-cancer (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater, Recurrent) in Australia (PO) (NCT04947189)
- 01 Jul 2022 Preclinical trials in Triple-negative-breast-cancer (Combination therapy) in Australia (PO) prior to July 2022
- 01 Jul 2021 Innocrin Pharmaceuticals in collaboration with St Vincent's Hospital plans a phase I/II trial for Breast cancer (Late-stage disease, Metastatic disease, Second-line therapy or greater, Combination therapy, Recurrent) in July 2021 (PO, Tablet) (NCT04947189)